The Drug Enforcement Administration on Tuesday proposed preserving the quantity of Schedule I marijuana that may be legally manufactured in the USA subsequent yr precisely the place it’s now, whereas saying it’s nonetheless figuring out methods to set manufacturing limits for the medical marijuana merchandise that moved to Schedule III earlier this yr.
The proposed 2027 mixture manufacturing quotas, printed within the Federal Register on Nov. 10 (91 FR 72566, Docket No. DEA-1730P), cowl each managed substance in Schedules I and II. Written and digital feedback are due on or earlier than Dec. 10, 2026.
Schedule I marijuana quotas unchanged
For 2027, DEA proposes an mixture manufacturing quota of 6,675,000 grams (about 6,675 kilograms) of marijuana and 1,000,000 grams of marijuana extract. It additionally proposes 1,523,040 grams of delta-9-tetrahydrocannabinol and 1,166,130 grams for the class listed as “all different tetrahydrocannabinol.”
All 4 figures match the 2026 quotas DEA finalized in a Federal Register discover printed Jan. 5, 2026. Combination manufacturing quotas set the whole quantity of every substance that DEA-registered producers could produce in a calendar yr to satisfy the nation’s estimated medical, scientific, analysis and industrial wants, lawful exports and reserve shares.
The desk additionally lists a 620-gram quota for artificial “cannabimimetic brokers” and a 30-gram quota for hexahydrocannabinol (HHC). DEA printed a discover in Could 2026 particularly itemizing HHC as a at present managed Schedule I substance.
Schedule III quotas nonetheless to come back
The extra consequential a part of the discover for the hashish business is what it leaves out. DEA factors to the April 28, 2026 remaining rule that moved two teams of marijuana merchandise from Schedule I to Schedule III: drug merchandise containing marijuana which were accredited by the Meals and Drug Administration, and drug merchandise topic to a state medical marijuana license.
That rule created three new drug codes for the Schedule III variations of those substances: marijuana (7362), marijuana extract (7353) and naturally derived delta-9-tetrahydrocannabinols (7386), every in an FDA-approved product or topic to a state medical marijuana license.
Based on the discover, the USA nonetheless has to satisfy its obligations underneath the 1961 Single Conference on Narcotic Medication, which lists marijuana in its personal Schedule I. Two of these management measures require producers and distributors of such medication to be licensed, and require licensed producers to get quotas that cap how a lot they’ll produce “to forestall extreme manufacturing and accumulation past that essential to fulfill reputable wants.”
DEA says it’s “at present within the technique of registering the producers and distributors who shall be dealing with the substances which were moved to schedule III” and is “assessing information sources and methodologies to find out essentially the most dependable and related datasets” for estimating reputable U.S. want and manufacturing necessities for the three new codes.
For that motive, the 2027 desk covers solely the Schedule I marijuana, marijuana extract and delta-9-THC codes (7360, 7350 and 7370). The company says a separate Federal Register discover will suggest quotas for codes 7362, 7353 and 7386 “as soon as the proposed APQs for the schedule III substances” are decided. It offers no timeline.
The registration course of DEA describes is already taking part in out for state-licensed operators. Hundreds of medical marijuana companies are nonetheless ready on federal registrations, as cannabisnews.org reported when DEA’s listing confirmed 6,083 medical marijuana companies nonetheless awaiting federal registration after the primary dispensary approvals. How DEA ultimately sizes the Schedule III quotas will matter to licensed cultivators and producers that register with the company, as a result of quotas set the federal ceiling on how a lot of a managed substance will be produced.
Psychedelic analysis quotas rise sharply
The discover additionally proposes massive will increase for a number of psychedelics in Schedule I, which DEA hyperlinks to rising scientific analysis and two government orders.
The proposed 2027 quota for MDMA is 33,296 grams, up from the 12,000 grams DEA set for 2026 in January. Ibogaine jumps to 12,002 grams from 210 grams. Psilocybin rises to 60,000 grams from 50,000, and psilocyn to 93,600 grams from 80,000. A number of different psychedelics keep at their 2026 ranges, together with DMT (25,000 grams), 5-MeO-DMT (30,000 grams), LSD (1,200 grams) and mescaline (1,200 grams).
DEA says the MDMA and ibogaine will increase are meant “to assist manufacturing actions associated to the elevated degree of analysis and scientific trials being carried out with these substances for potential remedy of situations together with post-traumatic stress dysfunction (PTSD) and despair.” It describes these will increase as measured towards its 2026 “proposed revised” ranges.
The company ties the will increase to Govt Order 14379, “Addressing Habit By means of the Nice American Restoration Initiative,” from Jan. 29, 2026, and Govt Order 14401, “Accelerating Medical Remedies for Severe Psychological Sickness,” from April 18, 2026. DEA says the second order requires a pathway for eligible sufferers to entry psychedelic medication, together with ibogaine compounds, underneath the federal Proper to Attempt Act.
Opioids down, different adjustments
On the Schedule II facet, DEA says the FDA predicts that medical use of Schedule II opioids in the USA will fall a median of 9.68 p.c in 2027 from 2026 ranges. DEA is proposing decrease quotas for fentanyl, hydrocodone (on the market), hydromorphone, oxycodone (on the market) and oxymorphone (on the market).
The company is proposing a better pentobarbital quota to construct a reserve stockpile underneath an government order on the Strategic Lively Pharmaceutical Substances Reserve. It’s also proposing a quota for O-desmethyltramadol for the primary time, after briefly inserting that substance in Schedule I in August. Quotas for acetyl fentanyl, heroin and fentanyl-related substances would drop.
In a separate remaining order printed the identical day, DEA adjusted the 2026 quotas for d,l-amphetamine, d-amphetamine (on the market), hydromorphone and methylphenidate (on the market).
What occurs subsequent
Feedback should reference Docket No. DEA-1730P and will be submitted via the federal eRulemaking portal at Rules.gov. Digital feedback shut at 11:59 p.m. Japanese Time on Dec. 10. DEA says the Administrator could maintain a public listening to on points raised within the feedback. After reviewing feedback, or after any listening to, the company will publish a remaining order setting the 2027 quotas.
For hashish, the larger open query is the separate Schedule III quota discover. Till it’s printed, the 2027 proposal units federal manufacturing limits just for marijuana that is still in Schedule I, not for the state-licensed medical marijuana merchandise that federal regulation now treats as Schedule III.
